Grifols (NASDAQ:GRFS) Shares Pass Above 200 Day Moving Average – Should You Sell?

Grifols, S.A. (NASDAQ:GRFS) shares crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $9.49 and traded as high as $9.52. Grifols shares last traded at $9.48, with a volume of 405,142 shares trading hands.

Analysts Set New Price Targets

Several research firms have recently weighed in on GRFS. Zacks Research downgraded shares of Grifols from a “hold” rating to a “strong sell” rating in a research note on Friday, December 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Grifols in a report on Wednesday, October 8th. Wall Street Zen upgraded Grifols from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Finally, JPMorgan Chase & Co. decreased their price objective on Grifols from $10.30 to $10.00 and set a “neutral” rating for the company in a report on Monday, December 8th. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.

Grifols Stock Performance

The business has a 50-day moving average price of $8.90 and a 200-day moving average price of $9.49. The company has a quick ratio of 0.93, a current ratio of 2.48 and a debt-to-equity ratio of 1.20. The firm has a market capitalization of $6.32 billion, a price-to-earnings ratio of 49.89, a P/E/G ratio of 0.32 and a beta of 0.67.

Hedge Funds Weigh In On Grifols

Several hedge funds have recently modified their holdings of GRFS. Brandes Investment Partners LP raised its stake in shares of Grifols by 8.9% in the second quarter. Brandes Investment Partners LP now owns 28,035,461 shares of the biotechnology company’s stock worth $253,441,000 after purchasing an additional 2,294,113 shares during the last quarter. Vinva Investment Management Ltd acquired a new position in Grifols in the 2nd quarter worth approximately $256,000. State of Wyoming acquired a new position in Grifols in the 2nd quarter worth approximately $1,729,000. Norges Bank acquired a new stake in Grifols during the 2nd quarter valued at approximately $17,538,000. Finally, Vestmark Advisory Solutions Inc. acquired a new stake in Grifols during the 2nd quarter valued at approximately $414,000.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.